{
    "clinical_study": {
        "@rank": "146318", 
        "brief_summary": {
            "textblock": "Within community with high incidence of HCC, stretching the limits could be justified based\n      on tumor characters and its biological behavior"
        }, 
        "brief_title": "Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits", 
        "completion_date": {
            "#text": "April 2012", 
            "@type": "Actual"
        }, 
        "condition": "Recurrence of HCC After LDLT", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Recurrence", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "detailed_description": {
            "textblock": "590 Egyptian patients underwent LDLT; of them, 172 (32%) patients were transplanted for HCC.\n      Twenty six cases (15.1%) were excluded due to early postoperative mortality (n=22) or due to\n      non HCC related mortality (n=4). One hundred forty six patients were retrospectively\n      reviewed to determine prognostic factors for recurrence."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Egyptien Patients with HCC\n\n          -  Patients within Milan Criteria\n\n          -  Patients beyond Milan criteria are selected on a case by case basis until 2005. From\n             2005 , patients beyond Milan criteria  are subjected to down staging protocol and\n             then reassessed (pre transplantation local ablative therapy either with RFA or TACE\n             according to the size and the site of the lesion and we wait  for 12 weeks after\n             ablation ,only those with well ablated lesions, decreased AFP and no denovo lesions\n             were transplanted).\n\n        Exclusion Criteria:\n\n          -  \u2022 Evidence of macro vascular invasion by CT portography and/or US duplex.\n\n               -  Metastatic HCC\n\n               -  General contraindications for LT (ongoing sepsis, other major co morbidities,\u2026).\n\n               -  Early postoperative mortality (first1 month).\n\n               -  Post transplant mortality during the period of follow up due to any cause other\n                  than recurrent HCC (e.g. sepsis, rejection, cardiological or cerebrovascular\n                  complications\u2026)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "62 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Egyptien Patient with HCC who underwent LDLT"
            }
        }, 
        "enrollment": {
            "#text": "590", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01937286", 
            "org_study_id": "Hepatocellular carcinaoma"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "LDLT,HCC, Microvascular invasion", 
        "lastchanged_date": "September 4, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cairo,", 
                    "country": "Egypt"
                }, 
                "name": "Ain Shams Center For Organ Transplantation (ASCOT),Ain Shams university"
            }
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_groups": "1", 
        "official_title": "Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Ministry of Health,organ transplantation committee,Egypt':'", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Recurrence of Hepatocellular carcinoma after LDLT", 
            "safety_issue": "Yes", 
            "time_frame": "at least 6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01937286"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ain Shams University", 
            "investigator_full_name": "Iman Fawzy Montasser", 
            "investigator_title": "Lecturer of Tropical Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Ain Shams University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ain Shams University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2002", 
        "study_design": "Observational Model: Case-Crossover, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}